IGFBP3 and inflammatory bowel disease: Apart from targeting IGFBP3/TMEM219, the use of PDOs provides an opportunity to assess alternative therapeutic options for patients with IBD and to increase our understanding of a primary role of intestinal epithelial cells or intestinal epithelial stem cells in the pathophysiology of IBD.